Elucid Names Richard E. Kuntz, MD, MSc and Shamiram Feinglass, MD, MPH Board Directors
BOSTON & SCCT ANNUAL MEETING, MONTREAL — Elucid, an AI medical technology company focused on providing physicians with a more precise view of atherosclerosis to drive patient-specific therapeutic decisions, has made two additions to its Board of Directors. The company named Richard E. Kuntz, MD, MSc and Shamiram Feinglass, MD, MPH as board directors.
Article content
These appointments will help guide Elucid as it accelerates its clinical research strategy, commercializes its flagship PlaqueIQ TM coronary plaque assessment technology, and continues development of its investigational FFR prediction model, based on PlaqueIQ. PlaqueIQ is the first and only FDA-cleared, non-invasive plaque analysis based on objective histology rather than subjective CCTA visual estimates. PlaqueIQ quantifies and classifies plaque morphology based on ground-truth histology, the gold standard for characterization of plaques. The software is designed to help physicians prioritize and personalize treatment based on actual disease, rather than population-based risk.
Article content
An experienced medical technology executive and clinical expert, Dr. Kuntz is former senior vice president and chief medical and scientific officer of Medtronic plc. Prior to joining Medtronic, he was the founder and chief scientific officer of the Harvard Clinical Research Institute (HCRI), a university-based contract research organization that coordinates National Institutes of Health (NIH) and industry clinical trials with the U.S. Food and Drug Administration (FDA). Dr. Kuntz has directed several multicenter clinical trials and has authored more than 250 original publications. Dr. Kuntz was an associate professor of Medicine at Harvard Medical School, chief of the division of Clinical Biometrics, and an interventional cardiologist in the division of cardiovascular diseases at the Brigham and Women's Hospital in Boston.
Article content
Dr. Feinglass is a managing director at Manatt Health working across the business, medical, and policy needs of health systems, life sciences, medical device, digital health and diagnostic companies globally. A global leader in health care, Dr. Feinglass has served as an executive and chief medical officer in large multi-national life sciences corporations including Danaher and Zimmer-Biomet. In parallel, she has driven policy changes alongside senior government officials around the world to influence health policy, regulation, and access. A former regulator at U.S. Centers for Medicare and Medicaid Services (CMS) and commander in the U.S. Public Health Service with extensive regulatory and legislative experience, Dr. Feinglass is on faculty at the John's Hopkins Bloomberg School of Public Health, Department of Mental Health and is a member of the Board of Directors of Sandoz AG.
Article content
'We are honored that Dr. Richard E. Kuntz and Dr. Shamiram Feinglass have joined Elucid's Board of Directors,' said Elucid CEO Kelly Huang, PhD. 'Rick lends an important and experienced interventional cardiology view, as well as expertise in clinical trial strategy and execution, and product innovation strategy. Coupled with Shami's unparalleled expertise in market access, policy making, and regulatory strategy, the two will be invaluable as we push forward our vision of a future where cardiac care is personalized, precision patient care versus risk factor and population-based care.'
Article content
About Elucid
Article content
Elucid is a Boston-based AI medical technology company dedicated to developing technology designed to provide physicians with a more precise view of atherosclerosis (coronary plaque buildup), the root cause of cardiovascular disease. The company's PlaqueIQ TM image analysis software is designed to help physicians prioritize and personalize treatment based on actual disease, rather than population-based risk of disease. PlaqueIQ includes the only FDA-cleared computed tomography angiography (CTA) algorithm that objectively quantifies plaque morphology validated against ground truth histology, the gold standard for characterization of plaque, as indicated by renowned pathologists. PlaqueIQ equips physicians with critical information regarding the type and amount of plaque in arteries that can lead to heart attack and stroke. Elucid is also pursuing an indication for FFR CT, derived from its plaque algorithm, to help identify coronary blockages and the extent of ischemia non-invasively. For more information, visit elucid.com.
Article content
Article content
Article content
Article content
Contacts
Article content
Media Contact:
Article content
Article content
Sam Choinski
Article content
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
National Post
20 minutes ago
- National Post
There is a serious side effect to going to space, NASA says
A new study from NASA, conducted over several years of long-duration spaceflights on the International Space Station, has found that more than half of U.S. astronauts started noticing changes in their vision after more than six months aboard the ISS. Here's what to know. Article content What does the study say? Article content Article content 'Many found that, as their mission progressed, they needed stronger reading glasses,' the study says. 'Researchers studying this phenomenon identified swelling in the optic disc, which is where the optic nerve enters the retina, and flattening of the eye shape.' Article content Article content What is causing it? Article content A Canadian-led study with an even longer acronym — Space Flight-Associated Neuro-ocular Syndrome Ocular Rigidity Investigation, or SANSORI — was carried out to determine whether stiffness of the eye, called ocular rigidity, contributes to development of SANS. Article content It studied 26 eyes (or 13 crew members) that spent between 157 and 186 days on the ISS, and revealed a drop in ocular rigidity (33 per cent), intraocular pressure (11 per cent) and ocular pulse amplitude (25 per cent) following the missions. 'These findings reveal previously unknown effects of microgravity on the eye's mechanical properties, contributing to a deeper understanding of … SANS,' researchers wrote. 'Long-term space missions significantly alter ocular biomechanics and have the potential to become biomarkers of disease progression.' Article content Article content What kinds of treatment have been tried? Article content Article content NASA has a study taking place now on the space station with a device called the Thigh Cuff. The ongoing investigation has 10 astronauts using tight leg cuffs to change the way fluid moves around inside the body, especially around the eyes and in the heart and blood vessels. Article content That study is expected to wrap up next year but, if successful, the team behind the device says, 'the cuffs could serve as a countermeasure against the problems associated with fluid shifts, including SANS.' Article content They add: 'A simple and easy-to-use tool to counter the headward shift of body fluids could help protect astronauts on future missions to the Moon and Mars. The cuffs also could treat conditions on Earth that cause fluid to build up in the head or upper body, such as long-term bed rest and certain diseases.' Article content Other possible treatments have been considered. Last year, a paper was published about an unnamed female astronaut with a particularly severe case of SANS. Her condition improved after she started taking a prescribed B-vitamin supplement that was flown to her on the station; however, there was coincidentally a reduction in cabin carbon dioxide at the same time, so researchers weren't certain if that may have also helped.
CTV News
20 minutes ago
- CTV News
Improving menopause care in B.C.
Vancouver Watch Millions of Canadian women experience menopause symptoms every year, but relatively little information or treatment is available for many of them.
CBC
20 minutes ago
- CBC
Mosquitos with West Nile virus have been detected in Mississauga: city
Social Sharing West Nile virus has been detected in some mosquitos in Peel Region, according to a news release Friday from the City of Mississauga. Infected mosquitoes were detected near Airport and Derry roads in Mississauga. While the risk of contracting the virus is low, the city is urging residents to protect themselves and their property from mosquitos. "There is no vaccine or specific treatment for humans, making prevention essential," says the city's release. West Nile virus is transmitted to humans from the bites of infected mosquitos. Symptoms can take two to 14 days to develop and include fever, headache, nausea, skin rash and body aches. People over the age of 50 or with weakened immune systems are at higher risk for complications. Mississauga says residents can try the following recommendations to limit mosquito exposure: Stay inside during peak mosquito hours at dusk and dawn. Apply insect repellents with DEET or Icaridin. Wear light-coloured protective clothing, like long sleeves and a hat. Empty and scrub standing water sources, like birdbaths, where mosquitos breed. Ensure windows and door screens fit securely.
